Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

JCH007 Apr. 22 at 3:32 PM

$JNJ Yeah...this decline makes sense. Not!

0 · Reply

prismmarketview Apr. 22 at 1:42 PM

$JNJ JNJ News Reports Sustained Efficacy of IMAAVY for Generalized Myasthenia Gravis https://prismmarketview.com/imaavy-sustained-disease-control-myasthenia-gravis/

0 · Reply

Bazzzigar Apr. 22 at 12:49 PM

$JNJ few more

0 · Reply

TraderSessionClear Apr. 22 at 9:53 AM

$JNJ

0 · Reply

DragonAlgo Apr. 22 at 9:13 AM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-24 | Strike: $225.00 | Type: CALL Option Plan (premium): Entry: $3.05 Stop: $2.20 TP1: $3.96 TP2: $5.18 TP3: $7.32 Momentum tape remains active. 🔗 https://dragonalgo.com

0 · Reply

ElliottwaveForecast Apr. 22 at 8:00 AM

Johnson & Johnson $JNJ Forecast — buyers should look to enter between the 227.8 – 215.8 area. Read the full blog for detailed Elliott Wave setup → https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #Elliottwave #Trading

0 · Reply

Pudgeman007 Apr. 21 at 10:56 PM

$JNJ This clown has no website! No bio, track record, selling on an E-commerce site. Hey stocktwits he spammed over 100 tickers in the last hour

0 · Reply

dosaman Apr. 21 at 10:31 PM

$JNJ when in doubt look at this. We will bounce back.

0 · Reply

MillionDollarSwingTrader Apr. 21 at 9:40 PM

$JNJ No spam, no fluff, just High-Probability options trades delivered. 7-Day Free Trial!! We are confident in our process. See for yourself: https://whop.com/million-dollar-swing-trader/trader-alerts/

0 · Reply

ElliottwaveForecast Apr. 21 at 9:38 PM

💊 $JNJ buyers should watch the Blue Box zone at 227.8–215.8 👀 This pullback looks corrective and could offer the next high-probability buying opportunity before the next leg higher resumes 📈 Don’t chase—wait for the right setup and trade with the trend. Read more: https://elliottwave-forecast.com/stock-market/jnj-forecast-buyers-should-enter-227-8-215-8-area/ #JNJ #Elliottwave #Stocks #Trading #Investing

0 · Reply

IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)

Apr 22, 2026, 4:00 AM EDT - 7 hours ago

Johnson & Johnson Announces CE Mark Approval for the New ETHICON™ 4000 Stapler

Apr 21, 2026, 4:22 PM EDT - 19 hours ago

Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Apr 21, 2026, 7:45 AM EDT - 1 day ago

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Apr 17, 2026, 10:36 PM EDT - 4 days ago

US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims

Apr 17, 2026, 7:00 PM EDT - 4 days ago

U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims

Apr 16, 2026, 10:16 AM EDT - 6 days ago

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

LLY MGTX

Apr 15, 2026, 4:11 PM EDT - 6 days ago

Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference

Apr 15, 2026, 1:43 PM EDT - 6 days ago

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results

Apr 15, 2026, 12:37 PM EDT - 6 days ago

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Apr 14, 2026, 10:51 AM EDT - 8 days ago

Johnson & Johnson CFO on the company's robotic surgical system

Apr 14, 2026, 10:30 AM EDT - 8 days ago

Tuesday's Morning Movers: ORCL & BE Extend Partnership, KMX & JNJ Earnings

ORCL BE KMX

Apr 14, 2026, 6:55 AM EDT - 8 days ago

J&J raises guidance for 2026 on strong start to the year

Apr 14, 2026, 6:25 AM EDT - 8 days ago

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

Apr 14, 2026, 6:21 AM EDT - 8 days ago

Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

Apr 14, 2026, 6:20 AM EDT - 8 days ago

J&J's First-Quarter Sales Grow on Cancer-Drug Strength

Apr 14, 2026, 6:20 AM EDT - 8 days ago

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

Apr 13, 2026, 11:36 AM EDT - 8 days ago

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

JPM DIA TRV

Apr 12, 2026, 2:00 PM EDT - 9 days ago

Goldman Sachs, Bank of America, JP Morgan, Netflix, J&J, Producer Prices, and More to Watch This Week

NFLX BAC GS JPM

Apr 10, 2026, 8:00 AM EDT - 12 days ago

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Apr 9, 2026, 7:57 AM EDT - 13 days ago

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Apr 8, 2026, 10:41 AM EDT - 14 days ago

Buy Johnson & Johnson Ahead of Earnings. The Stock's Run-Up Isn't Over.

Apr 7, 2026, 8:00 AM EDT - 15 days ago

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Mar 30, 2026, 9:14 AM EDT - 23 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Mar 28, 2026, 10:00 AM EDT - 25 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 27, 2026, 4:46 PM EDT - 25 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 6:31 AM EDT - 26 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 19, 2026, 1:00 PM EDT - 4 weeks ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

Mar 19, 2026, 9:35 AM EDT - 4 weeks ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 18, 2026, 2:23 PM EDT - 4 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

Mar 18, 2026, 1:17 PM EDT - 4 weeks ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 8:31 AM EDT - 5 weeks ago

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 7:49 AM EDT - 5 weeks ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 16, 2026, 11:00 AM EDT - 5 weeks ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 13, 2026, 12:35 PM EDT - 5 weeks ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 5 weeks ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 6 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 6 weeks ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 6 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 8:03 AM EST - 7 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 7 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 26, 2026, 2:30 PM EST - 7 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 2 months ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 2 months ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 2 months ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 2 months ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 2 months ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:00 PM EST - 2 months ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 2 months ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 2 months ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

JCH007 Apr. 22 at 3:32 PM

$JNJ Yeah...this decline makes sense. Not!

0 · Reply

prismmarketview Apr. 22 at 1:42 PM

$JNJ JNJ News Reports Sustained Efficacy of IMAAVY for Generalized Myasthenia Gravis https://prismmarketview.com/imaavy-sustained-disease-control-myasthenia-gravis/

0 · Reply

Bazzzigar Apr. 22 at 12:49 PM

$JNJ few more

0 · Reply

TraderSessionClear Apr. 22 at 9:53 AM

$JNJ

0 · Reply

DragonAlgo Apr. 22 at 9:13 AM

0 · Reply

ElliottwaveForecast Apr. 22 at 8:00 AM

0 · Reply

Pudgeman007 Apr. 21 at 10:56 PM

$JNJ This clown has no website! No bio, track record, selling on an E-commerce site. Hey stocktwits he spammed over 100 tickers in the last hour

0 · Reply

dosaman Apr. 21 at 10:31 PM

$JNJ when in doubt look at this. We will bounce back.

0 · Reply

MillionDollarSwingTrader Apr. 21 at 9:40 PM

0 · Reply

ElliottwaveForecast Apr. 21 at 9:38 PM

0 · Reply

MHM7700 Apr. 21 at 8:45 PM

$JNJ 05/01 220p $2.02

0 · Reply

SenefAS Apr. 21 at 8:16 PM

$GMAB Genmab a lot of options tonight… Something is cooking 🤔 $NVO $JNJ

1 · Reply

frontiere Apr. 21 at 7:16 PM

$JNJ Johnson & Johnson ref=$226 — NO pstn but maybe would short >239 ? Similar to NVS 👇, a multi-year breakout?

0 · Reply

DDaphne52 Apr. 21 at 6:32 PM

$JNJ breaking down

0 · Reply

deltax10 Apr. 21 at 5:13 PM

$JNJ buy 500 shares at 226, since then going down Officially bag holder 🤣🤣🤣

0 · Reply

RamGuy_949322 Apr. 21 at 4:55 PM

$JNJ good buy here

0 · Reply

TalkMarkets Apr. 21 at 4:51 PM

Johnson & Johnson Forecast: Buyers Should Enter Between 227.8 - 215.8 Area $JNJ https://talkmarkets.com/article/johnson-johnson-forecast-buyers-should-enter-between-2278---2158-area-1776790250

0 · Reply

Aporia Apr. 21 at 4:28 PM

$JNJ build range now, and consolidate for 4 years?

0 · Reply

mr_Apex Apr. 21 at 4:23 PM

$JNJ 05/01 220p $2.02 🏌🏽

0 · Reply

PickAlpha Apr. 21 at 3:55 PM

3/5: Eli Lilly to buy Kelonia Therapeutics for $3.25B upfront plus milestones (up to $7B total); close expected 2H26 | View: The deal adds oncology optionality… $LLY $JNJ $GILD $XBI $IBB

0 · Reply

Arcides Apr. 21 at 3:32 PM

$JNJ that breakdown had follow through...

0 · Reply

yellowstar16 Apr. 21 at 3:26 PM

$JNJ added. 🛒🛒🛒🛒

0 · Reply

Market Cap	555.64B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	21.82
Forward PE	20.24
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	11,681,200
Avg Vol	8,294,324
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	7%
Beta	0.34
Analysts	Strong Sell
Price Target	$253.84